127 related articles for article (PubMed ID: 16258255)
1. Chemical inhibition of Wip1 phosphatase contributes to suppression of tumorigenesis.
Belova GI; Demidov ON; Fornace AJ; Bulavin DV
Cancer Biol Ther; 2005 Oct; 4(10):1154-8. PubMed ID: 16258255
[TBL] [Abstract][Full Text] [Related]
2. Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction.
Gilmartin AG; Faitg TH; Richter M; Groy A; Seefeld MA; Darcy MG; Peng X; Federowicz K; Yang J; Zhang SY; Minthorn E; Jaworski JP; Schaber M; Martens S; McNulty DE; Sinnamon RH; Zhang H; Kirkpatrick RB; Nevins N; Cui G; Pietrak B; Diaz E; Jones A; Brandt M; Schwartz B; Heerding DA; Kumar R
Nat Chem Biol; 2014 Mar; 10(3):181-7. PubMed ID: 24390428
[TBL] [Abstract][Full Text] [Related]
3. Wip1-deficient mice are resistant to common cancer genes.
Harrison M; Li J; Degenhardt Y; Hoey T; Powers S
Trends Mol Med; 2004 Aug; 10(8):359-61. PubMed ID: 15310454
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway.
Zhang X; Wan G; Mlotshwa S; Vance V; Berger FG; Chen H; Lu X
Cancer Res; 2010 Sep; 70(18):7176-86. PubMed ID: 20668064
[TBL] [Abstract][Full Text] [Related]
5. Hormone-sensing cells require Wip1 for paracrine stimulation in normal and premalignant mammary epithelium.
Tarulli GA; De Silva D; Ho V; Kunasegaran K; Ghosh K; Tan BC; Bulavin DV; Pietersen AM
Breast Cancer Res; 2013 Jan; 15(1):R10. PubMed ID: 23369183
[TBL] [Abstract][Full Text] [Related]
6. Wip1 directly dephosphorylates gamma-H2AX and attenuates the DNA damage response.
Cha H; Lowe JM; Li H; Lee JS; Belova GI; Bulavin DV; Fornace AJ
Cancer Res; 2010 May; 70(10):4112-22. PubMed ID: 20460517
[TBL] [Abstract][Full Text] [Related]
7. The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis.
Demidov ON; Kek C; Shreeram S; Timofeev O; Fornace AJ; Appella E; Bulavin DV
Oncogene; 2007 Apr; 26(17):2502-6. PubMed ID: 17016428
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway.
Bulavin DV; Phillips C; Nannenga B; Timofeev O; Donehower LA; Anderson CW; Appella E; Fornace AJ
Nat Genet; 2004 Apr; 36(4):343-50. PubMed ID: 14991053
[TBL] [Abstract][Full Text] [Related]
9. WIP1 phosphatase as a potential therapeutic target in neuroblastoma.
Richter M; Dayaram T; Gilmartin AG; Ganji G; Pemmasani SK; Van Der Key H; Shohet JM; Donehower LA; Kumar R
PLoS One; 2015; 10(2):e0115635. PubMed ID: 25658463
[TBL] [Abstract][Full Text] [Related]
10. HDM2 promotes WIP1-mediated medulloblastoma growth.
Buss MC; Read TA; Schniederjan MJ; Gandhi K; Castellino RC
Neuro Oncol; 2012 Apr; 14(4):440-58. PubMed ID: 22379189
[TBL] [Abstract][Full Text] [Related]
11. Development of a substrate-based cyclic phosphopeptide inhibitor of protein phosphatase 2Cdelta, Wip1.
Yamaguchi H; Durell SR; Feng H; Bai Y; Anderson CW; Appella E
Biochemistry; 2006 Nov; 45(44):13193-202. PubMed ID: 17073441
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers.
Yu E; Ahn YS; Jang SJ; Kim MJ; Yoon HS; Gong G; Choi J
Breast Cancer Res Treat; 2007 Mar; 101(3):269-78. PubMed ID: 16897432
[TBL] [Abstract][Full Text] [Related]
13. Wip1 phosphatase in breast cancer.
Emelyanov A; Bulavin DV
Oncogene; 2015 Aug; 34(34):4429-38. PubMed ID: 25381821
[TBL] [Abstract][Full Text] [Related]
14. Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy.
Clausse V; Goloudina AR; Uyanik B; Kochetkova EY; Richaud S; Fedorova OA; Hammann A; Bardou M; Barlev NA; Garrido C; Demidov ON
Cell Death Dis; 2016 Apr; 7(4):e2195. PubMed ID: 27077811
[TBL] [Abstract][Full Text] [Related]
15. Novel inhibitors targeting PPM1D phosphatase potently suppress cancer cell proliferation.
Ogasawara S; Kiyota Y; Chuman Y; Kowata A; Yoshimura F; Tanino K; Kamada R; Sakaguchi K
Bioorg Med Chem; 2015 Oct; 23(19):6246-9. PubMed ID: 26358280
[TBL] [Abstract][Full Text] [Related]
16. Off-target response of a Wip1 chemical inhibitor in skin keratinocytes.
Lee JS; Park JR; Kwon OS; Kim H; Fornace AJ; Cha HJ
J Dermatol Sci; 2014 Feb; 73(2):125-34. PubMed ID: 24126074
[TBL] [Abstract][Full Text] [Related]
17. The estrogen receptor alpha pathway induces oncogenic Wip1 phosphatase gene expression.
Han HS; Yu E; Song JY; Park JY; Jang SJ; Choi J
Mol Cancer Res; 2009 May; 7(5):713-23. PubMed ID: 19435816
[TBL] [Abstract][Full Text] [Related]
18. WIP1 phosphatase at the crossroads of cancer and aging.
Le Guezennec X; Bulavin DV
Trends Biochem Sci; 2010 Feb; 35(2):109-14. PubMed ID: 19879149
[TBL] [Abstract][Full Text] [Related]
19. Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase.
Shreeram S; Hee WK; Demidov ON; Kek C; Yamaguchi H; Fornace AJ; Anderson CW; Appella E; Bulavin DV
J Exp Med; 2006 Dec; 203(13):2793-9. PubMed ID: 17158963
[TBL] [Abstract][Full Text] [Related]
20. The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma variants.
Buss MC; Remke M; Lee J; Gandhi K; Schniederjan MJ; Kool M; Northcott PA; Pfister SM; Taylor MD; Castellino RC
Oncogene; 2015 Feb; 34(9):1126-40. PubMed ID: 24632620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
